Business
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Co...
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded
About this update from Immunic, Inc.
[{"type":"text","content":"Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis \n Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022\n\n\nNEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis Organization (ECCO).\n\n \n \n \n \n \n \n\n \nThe poster, entitled, \"Vidofludimus Calcium (IMU-838), a Small Molecule DHODH Inhibitor in Phase 2 Clinical Trial for Ulcerative Colitis, Shows Potent Anti-inflammatory Activity in Cell-Culture-Based Systems\" (Abstract Number: EC22-1109, Poster Number: P064), will be presented during the Virtual Poster Exhibition – Basic Science / ePosters being held today. The poster presentation will also be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.\nHighlights include:\nVidofludimus calcium reduces proinflammatory immune cell responses by inducing regulatory macrophages, reducing pro-inflammatory cytokine secretion and reducing T cell proliferation. Vidofludimus calcium shows an additive to synergistic effect with anti-TNF antibodies in a mixed lymphocyte reaction assay, suggesting a new and promising potential combination treatment opportunity for ulcerative colitis (UC). DHODH is important in cells that receive a strong immune stimulus and are highly metabolically active. In support, vidofludimus calcium was observed to show a biological selectivity by only targeting these hyperactive cells and, thus, allows for a normal immune response against pathogens and towards vaccines, representing a medically relevant advantage for treatment of patients with inflammatory bowel disease.Additionally, Immunic announces the blinded baseline characteristics ...